Checking ELVN unusual options activity helps you spot when traders are making outsized bets on Enliven Therapeutics Inc before the broader market catches on. Enliven Therapeutics Inc's unusual options activity flags contracts trading at multiples of their average daily volume, often signaling that informed money is positioning ahead of a catalyst. Use our scanner to monitor ELVN unusual options activity today and surface the prints that deserve a second look.
Unusual options flow typically refers to trades where volume vastly exceeds open interest at a given strike, or where total contract volume on a name spikes well above its norm. Watching ELVN unusual options flow today can reveal large block trades, sweeps across exchanges, and aggressive directional bets. Tracking ELVN unusual options volume across calls and puts helps you separate hedging activity from genuinely speculative positioning, and ELVN unusual options flow data becomes especially valuable around earnings, product launches, and macro events.
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its pipeline of small molecule kinase inhibitors include ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial has been activated to evaluate people with cancers harboring an abnormal HER2 gene. The company is based in Boulder, Colorado.
Catalysts rarely arrive without a footprint, and ELVN unusual options activity is often where that footprint shows up first. Our scanner tracks Enliven Therapeutics Inc's unusual options flow in real time, ranks prints by volume-to-open-interest, premium spent, and aggressor side, and separates real conviction from noise. Whether you're looking at ELVN unusual options volume on the call side or chasing put sweeps, Enliven Therapeutics Inc's unusual options flow today is one click away, so put it on your radar before the headlines hit.
